Court Rules ‘Pay-To-Delay’ Deal Anti-Competitive
A federal appeals court agrees with the Federal Trade Commission that a 2010 deal between Endo International and Impax Laboratories to delay a generic version of Endo’s painkiller for three years in exchange for $112 million was anti-competitive. And drug makers try to prepare for the next viral pandemic.
Stat:
Appeals Court Upholds FTC View Of Controversial Pay-To-Delay Settlements
In what is being called a win for consumers, a U.S. appeals court upheld a decision by the Federal Trade Commission that a so-called pay-to-delay deal between two drug makers was anti-competitive. At issue was a deal reached in 2010 between Endo International (ENDP) and Impax Laboratories, which agreed not to market a generic version of the Endo’s Opana ER painkiller for three years in exchange for $112 million. (Silverman, 4/13)
Nature:
The Race For Antiviral Drugs To Beat COVID — And The Next Pandemic
Despite dire warnings, a stockpile of ready compounds to fight viral pandemics was sorely lacking. Can drugmakers finally do the right thing? Despite dire warnings, a stockpile of ready compounds to fight viral pandemics was sorely lacking. Can drugmakers finally do the right thing? (Dolgin, 4/14)
In other health industry news —
Stat:
Mayo Clinic Launches Two Companies To Tap Patient Data For AI Tools
Mayo Clinic is forming a pair of companies to collect and analyze data from remote monitoring devices and diagnostic tools, a move that comes as part of a broader bid to harness patient data to deliver continuous care guided by artificial intelligence. The ultimate goal of the companies is to deliver more precise physiological information to patients and doctors around the clock, allowing them to make faster decisions to head off disease and deliver care without the usual morass of extra office visits and trips to the pharmacy. (Ross, 4/14)
